image
Standard BioTools Inc. LAB
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
Watchlist
$ 1.35
-1.46 %
$ 513 M
Market Cap
-4.22
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one LAB stock under the worst case scenario is HIDDEN Compared to the current market price of 1.35 USD, Standard BioTools Inc. is HIDDEN

LAB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one LAB stock under the base case scenario is HIDDEN Compared to the current market price of 1.35 USD, Standard BioTools Inc. is HIDDEN

LAB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one LAB stock under the best case scenario is HIDDEN Compared to the current market price of 1.35 USD, Standard BioTools Inc. is HIDDEN

LAB Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart LAB

image
1M 25%
6M -31%
1Y -45%
3Y -19%
5Y -334%
All
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.815 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
174 M REVENUE
64.03%
Growth Rates
1Year 64.03%
3Years 10.13%
5Years 8.27%
7Years 7.98%
10Years 4.12%
-175 M OPERATING INCOME
-128.77%
Growth Rates
1Year -128.77%
3Years -37.47%
5Years -27.58%
7Years -17.01%
10Years -12.95%
-139 M NET INCOME
-86.03%
Growth Rates
1Year -86.03%
3Years -32.85%
5Years -16.47%
7Years -12.60%
10Years -10.15%
-143 M OPERATING CASH FLOW
-231.40%
Growth Rates
1Year -231.40%
3Years -48.21%
5Years -32.44%
7Years -29.03%
10Years -20.29%
363 M INVESTING CASH FLOW
1694.60%
Growth Rates
1Year 1694.60%
3Years 218.80%
5Years 62.24%
7Years 54.03%
10Years 14.97%
-103 M FINANCING CASH FLOW
-1407.06%
Growth Rates
1Year -1407.06%
3Years -95.13%
5Years -106.75%
7Years -24.12%
10Years -4.22%
40.8 M REVENUE
-12.68%
Growth Rates
1Year 64.03%
3Years 10.13%
5Years 8.27%
7Years 7.98%
10Years 4.12%
-33 M OPERATING INCOME
-0.47%
Growth Rates
1Year -128.77%
3Years -37.47%
5Years -27.58%
7Years -17.01%
10Years -12.95%
-26 M NET INCOME
23.59%
Growth Rates
1Year -86.03%
3Years -32.85%
5Years -16.47%
7Years -12.60%
10Years -10.15%
-30.3 M OPERATING CASH FLOW
-115.40%
Growth Rates
1Year -231.40%
3Years -48.21%
5Years -32.44%
7Years -29.03%
10Years -20.29%
14.6 M INVESTING CASH FLOW
-43.15%
Growth Rates
1Year 1694.60%
3Years 218.80%
5Years 62.24%
7Years 54.03%
10Years 14.97%
-46 K FINANCING CASH FLOW
99.92%
Growth Rates
1Year -1407.06%
3Years -95.13%
5Years -106.75%
7Years -24.12%
10Years -4.22%
Balance Sheet Standard BioTools Inc.
image
Current Assets 376 M
Cash & Short-Term Investments 293 M
Receivables 33.6 M
Other Current Assets 49.4 M
Non-Current Assets 236 M
Long-Term Investments 0
PP&E 71.4 M
Other Non-Current Assets 165 M
47.83 %5.49 %8.07 %11.66 %26.96 %Total Assets$612.3m
Current Liabilities 65.9 M
Accounts Payable 12.3 M
Short-Term Debt 12.5 M
Other Current Liabilities 41.2 M
Non-Current Liabilities 74.7 M
Long-Term Debt 26.8 M
Other Non-Current Liabilities 48 M
8.73 %8.86 %29.27 %19.04 %34.11 %Total Liabilities$140.6m
EFFICIENCY
Earnings Waterfall Standard BioTools Inc.
image
Revenue 174 M
Cost Of Revenue 90.2 M
Gross Profit 84.3 M
Operating Expenses 259 M
Operating Income -175 M
Other Expenses -36.4 M
Net Income -139 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)174m(90m)84m(259m)(175m)36m(139m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
48.31% GROSS MARGIN
48.31%
Averages
1Year 48.31%
3Years 44.53%
5Years 49.40%
7Years 50.92%
10Years 52.27%
-100.46% OPERATING MARGIN
-100.46%
Averages
1Year -100.46%
3Years -97.04%
5Years -75.95%
7Years -66.66%
10Years -63.76%
-79.62% NET MARGIN
-79.62%
Averages
1Year -79.62%
3Years -114.64%
5Years -85.53%
7Years -76.45%
10Years -71.38%
-29.44% ROE
-29.44%
Averages
1Year -29.44%
3Years 52.72%
5Years 11.48%
7Years -9.51%
10Years -45.14%
-22.68% ROA
-22.68%
Averages
1Year -22.68%
3Years -31.50%
5Years -26.47%
7Years -25.18%
10Years -23.65%
-31.48% ROIC
-31.48%
Averages
1Year -31.48%
3Years -30.46%
5Years -27.22%
7Years -24.98%
10Years -23.61%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Standard BioTools Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -139 M
Depreciation & Amortization 4.35 M
Capital Expenditures -8.36 M
Stock-Based Compensation 31.7 M
Change in Working Capital -29.2 M
Others -39.3 M
Free Cash Flow -152 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Standard BioTools Inc.
image
LAB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Standard BioTools Inc.
image
Sold
0-3 MONTHS
57.5 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
5.13 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
12.6 M USD 1
9-12 MONTHS
7. News
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. prnewswire.com - 2 weeks ago
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business    Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”), including SomaScan® Assay Services, Authorized Sites and KREX™ for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep). globenewswire.com - 2 weeks ago
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development globenewswire.com - 1 month ago
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Call Participants Kyle Boucher - TD Cowen Matt Stanton - Jefferies Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 2 months ago
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago. zacks.com - 2 months ago
Standard BioTools Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. globenewswire.com - 2 months ago
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. globenewswire.com - 2 months ago
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. globenewswire.com - 2 months ago
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: globenewswire.com - 4 months ago
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. seekingalpha.com - 4 months ago
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. globenewswire.com - 4 months ago
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. globenewswire.com - 4 months ago
8. Profile Summary

Standard BioTools Inc. LAB

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 513 M
Dividend Yield 0.00%
Description Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Contact 2 Tower Place, South San Francisco, CA, 94080 https://www.fluidigm.com
IPO Date Feb. 10, 2011
Employees 814
Officers Mr. Hanjoon Kim Chief Financial Officer Mr. Jonathan Mickelsen Vice President & Chief Accounting Officer Dr. Michael Egholm Ph.D. President, Chief Executive Officer & Director Ms. Elizabeth R. Jensen Chief Human Resources Officer Mr. Sean Mackay Chief Business Officer & Senior Vice President John Graziano Vice President of Investor Relations Dr. Stephen A. Williams BS, MB, Ph.D. Chief Medical Officer